An observational study in Autism Spectrum Disorder, sponsored by Stalicla SA. Recruiting at 21 sites in 3 countries. Open to participants aged 12 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-17.
Sponsored by Stalicla SA · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 773 studies in Autism Spectrum Disorder with a site in United States — 163 open to participants now, 203 under way, 9 of them phase 3. Autism Spectrum Disorder · United States.
Among the 773 studies in Autism Spectrum Disorder with a site in United States, this one is the 6th largest by planned enrollment of the 114 observational ones that give a count, is one of 57 that started in 2022, is one of 114 observational ones, reaches primary completion later than 81 of the 201 other live ones, and was the 574th registered.
1,733 studies on the registry are indexed under Autism Spectrum Disorder; 503 are open to participants now.
Browse Autism Spectrum Disorder studies →163 of the 773 studies in Autism Spectrum Disorder with a site in United States are open now. Recruiting first, the newest first:
New York State Institute for Basic Research · Sites in United States
Ages 5–12
Northeastern University · Sites in United States
Ages 33 mo–71 mo
Massachusetts General Hospital · Sites in United States
Ages 12–17
Schweitzer Engineering Laboratories · Sites in United States
Ages 24 mo–60 mo · Healthy volunteers
Children's Hospital Medical Center, Cincinnati · Sites in United States
Ages 12–18
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 351 Autism Spectrum Disorder studies recruiting now, 48 (14%) set no upper age limit and 296 (84%) stop at 75 or younger; 301 take children under 18; 92 take healthy volunteers.
This study: 12 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
773 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 52 · Phase 2 117 · Phase 3 33 · Phase 4 16
First in 2004; this study’s year is marked. 57 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,500 is above the median of 103 across 323 observational studies indexed under Autism Spectrum Disorder.
Median enrollment 50 across the 658 interventional studies, 132 across the 114 observational. Of the 523 that completed or were terminated, 174 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
89 of 773 have an industry lead sponsor. The 10 most frequent:
Stalicla SA is the lead sponsor of 5 studies on the registry; 1 is open to participants now.
Stalicla SA has 4 studies filed under Autism Spectrum Disorder — fewer than ten, so there is no comparison to draw.
69 of the studies in Autism Spectrum Disorder with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06706674Phase 3Intra-Cellular Therapies, Inc.Multicenter Study of Lumateperone for the Treatment of Irritability Associated With Autism Spectrum Disorder (ASD) in Pediatric Patients | 2027-06-21 |
| NCT06690398Phase 3Intra-Cellular Therapies, Inc.Multicenter Study of Lumateperone for the Treatment of Irritability Associated With Autism Spectrum Disorder in Pediatric Patients | 2027-06-21 |
| NCT07670000Natalia PoluektovaMental And Speech Developmental Delay Autism Spectrum-Type Behavioral Disorder | 2026-11 |
| NCT04242355Yale UniversityTranscranial Magnetic Stimulation on Neural and Behavioral Facets of Social Cognition in Autism Spectrum Disorder | 2026-12 |
| NCT06059352Loma Linda UniversitySleep and Central Auditory Processing Disorder in Autism Spectrum Disorder | 2026-12 |
Add all 69 to your calendar (.ics) → With an account.
Among the 773 studies in Autism Spectrum Disorder with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To determine sufficient number of biological and clinical markers to identify subgroups of potential best responders to a specific medication
Male or female individuals with an autism diagnosis as defined by the DSM-5, adults (from 18 to 65 years of age, inclusive) and adolescents (from 12 to 17 years of age, inclusive).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinical characterisation of the ASD-Phen1 and ASD-Phen2 subpopulations.
A semi-structured medical questionnaire will be administered to collect clinical (sign and symptoms) and anthropomorphic features.
Time frame: Day 0
Molecular characterization of the ASD-Phen1 and ASD-Phen2 subpopulations
Better characterize subpopulations of ASD subjects and potentially identify/confirm a molecular signature specific of each subpopulation.
Time frame: Day 0
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Started Oct 2022 (actual). Primary completion is estimated for Mar 2027, 53 months after the start.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Stalicla SA